Eidos Therapeutics, Inc. (EIDX) Financial Statements (2024 and earlier)
Company Profile
Business Address |
101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO, CA 94104 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 174,821 | 196,515 | 191,157 | 165,822 | 131,400 | 147,064 | |||
Cash and cash equivalents | 174,821 | 196,515 | 191,157 | 165,822 | 131,400 | 147,064 | |||
Receivables | 154 | 125 | 85 | 83 | 197 | 72 | |||
Other undisclosed current assets | 3,818 | 3,952 | 4,678 | 5,402 | 3,928 | 2,160 | |||
Total current assets: | 178,793 | 200,592 | 195,920 | 171,307 | 135,525 | 149,296 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 3,781 | 3,897 | 4,010 | 4,121 | |||||
Property, plant and equipment | 1,317 | 1,283 | 1,259 | 1,199 | 204 | 196 | |||
Other noncurrent assets | 2,779 | 2,825 | 2,631 | 2,267 | 2,564 | 2,652 | |||
Other undisclosed noncurrent assets | 988 | 1,053 | |||||||
Total noncurrent assets: | 7,877 | 8,005 | 7,900 | 7,587 | 3,756 | 3,901 | |||
TOTAL ASSETS: | 186,670 | 208,597 | 203,820 | 178,894 | 139,281 | 153,197 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 8,815 | 5,286 | 5,449 | 5,880 | 3,120 | 4,210 | |||
Employee-related liabilities | 1,210 | 730 | 1,865 | 1,416 | 1,102 | 670 | |||
Accounts payable | 2,240 | 3,972 | 3,151 | 3,567 | 1,842 | 3,212 | |||
Accrued liabilities | 5,365 | 584 | 433 | 897 | 176 | 328 | |||
Debt | 569 | 554 | 471 | ||||||
Deferred compensation liability | 133 | 138 | 143 | 145 | 147 | 147 | |||
Due to related parties | 359 | 323 | 316 | 372 | 344 | 407 | |||
Other undisclosed current liabilities | 6,082 | 5,504 | 3,968 | 3,207 | 2,878 | 3,077 | |||
Total current liabilities: | 15,389 | 11,820 | 10,430 | 10,075 | 6,489 | 7,841 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation | 20,815 | 20,759 | 20,703 | 4,736 | |||||
Long-term debt, excluding current maturities | 16,522 | 16,316 | 16,112 | ||||||
Liabilities, other than long-term debt | 1,155 | 1,166 | 1,260 | 129 | 164 | 201 | |||
Other liabilities | 31 | 63 | 95 | 129 | 164 | 201 | |||
Operating lease, liability | 4,293 | 4,443 | 4,591 | 4,736 | |||||
Derivative instruments and hedges, liabilities | 1,124 | 1,103 | 1,165 | ||||||
Other undisclosed noncurrent liabilities | 782 | 854 | |||||||
Total noncurrent liabilities: | 21,970 | 21,925 | 21,963 | 4,865 | 946 | 1,055 | |||
Total liabilities: | 37,359 | 33,745 | 32,393 | 14,940 | 7,435 | 8,896 | |||
Equity | |||||||||
Equity, attributable to parent | 149,311 | 174,852 | 171,427 | 163,954 | 131,846 | 144,301 | |||
Common stock | 39 | 39 | 38 | 38 | 37 | 37 | |||
Additional paid in capital | 304,050 | 300,742 | 274,494 | 248,041 | 222,865 | 221,267 | |||
Accumulated deficit | (154,778) | (125,929) | (103,105) | (84,125) | (91,056) | (77,003) | |||
Total equity: | 149,311 | 174,852 | 171,427 | 163,954 | 131,846 | 144,301 | |||
TOTAL LIABILITIES AND EQUITY: | 186,670 | 208,597 | 203,820 | 178,894 | 139,281 | 153,197 |
Income Statement (P&L) ($ in thousands)Annual | Quarterly
9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 26,691 | |||||||
Cost of revenue (Cost of Goods and Services Sold) | (2,500) | |||||||
Gross profit: | 24,191 | |||||||
Operating expenses | (28,397) | (22,913) | (19,344) | (17,940) | (14,794) | (12,584) | ||
Other undisclosed operating income | 156 | 27 | 20 | |||||
Operating income (loss): | (28,241) | (22,886) | (19,324) | 6,251 | (14,794) | (12,584) | ||
Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (4) | 580 | 671 | 680 | 741 | 851 | ||
Interest and debt expense | (604) | (518) | ||||||
Other undisclosed loss from continuing operations before equity method investments, income taxes | (327) | |||||||
Income (loss) from continuing operations: | (28,849) | (22,824) | (18,980) | 6,931 | (14,053) | (11,733) | ||
Income (loss) before gain (loss) on sale of properties: | (28,849) | (22,824) | (18,980) | 6,931 | (14,053) | (11,733) | ||
Net income (loss) available to common stockholders, diluted: | (28,849) | (22,824) | (18,980) | 6,931 | (14,053) | (11,733) |
Comprehensive Income ($ in thousands)Annual | Quarterly
9/30/2020 Q3 | 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | ||
---|---|---|---|---|---|---|---|---|
Net income (loss): | (28,849) | (22,824) | (18,980) | 6,931 | (14,053) | (11,733) | ||
Comprehensive income (loss), net of tax, attributable to parent: | (28,849) | (22,824) | (18,980) | 6,931 | (14,053) | (11,733) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.